Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Free Cash Flow (2019 - 2025)

Cyclerion Therapeutics has reported Free Cash Flow over the past 7 years, most recently at -$264000.0 for Q3 2025.

  • Quarterly results put Free Cash Flow at -$264000.0 for Q3 2025, up 84.62% from a year ago — trailing twelve months through Sep 2025 was -$1.4 million (up 77.94% YoY), and the annual figure for FY2024 was -$4.3 million, up 79.6%.
  • Free Cash Flow for Q3 2025 was -$264000.0 at Cyclerion Therapeutics, up from -$503000.0 in the prior quarter.
  • Over the last five years, Free Cash Flow for CYCN hit a ceiling of $360000.0 in Q4 2024 and a floor of -$14.5 million in Q1 2021.
  • Median Free Cash Flow over the past 5 years was -$6.2 million (2023), compared with a mean of -$5.5 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 96.37% in 2022 and later skyrocketed 123.36% in 2024.
  • Cyclerion Therapeutics' Free Cash Flow stood at -$8.6 million in 2021, then increased by 18.39% to -$7.0 million in 2022, then skyrocketed by 78.12% to -$1.5 million in 2023, then skyrocketed by 123.36% to $360000.0 in 2024, then plummeted by 173.33% to -$264000.0 in 2025.
  • The last three reported values for Free Cash Flow were -$264000.0 (Q3 2025), -$503000.0 (Q2 2025), and -$968000.0 (Q1 2025) per Business Quant data.